-

Rising Pharmaceuticals Bolsters U.S. Supply Chain by Expanding Sterile Dosage Capabilities, Including Injectables and Ophthalmics, with Opening of New Facility

Optimizes supply chain security by strategically locating manufacturing site in Decatur, Illinois

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Rising Pharma Holdings Inc., dba as Rising Pharmaceuticals, today announced the opening of a commercial manufacturing facility in Decatur, Illinois, to manufacture and package sterile products, including injectables and ophthalmic products in response to critical pharmaceutical supply shortages in the U.S. The site comprises a manufacturing and packaging facility spanning a combined 230,000 square feet. The move is expected to augment Rising’s existing product portfolio and offer a wider basket of products for customers.

“Rising Pharmaceuticals is proud to play a significant role supporting the healthcare system by producing more than 180 commercialized generic medicines and over 620 active SKU on the market. With one of the broadest portfolios of any U.S. generic pharmaceuticals company, we recognize that expanding manufacturing capabilities in the U.S. is mission-critical for our continued commercial success, as well as for public health in general,” said Vimal Kavuru, CEO of Rising Pharmaceuticals. “The new facility will adhere to stringent quality standards to produce generic medications that are effective and cost-efficient.”

“We look forward to creating a model of sustainable development through our partnership with the Decatur community, balancing efficient U.S. manufacturing growth while competing in the global pharmaceutical supply chain,” said Steven Coventry, Vice President of Operations and General Manager, Rising Pharmaceuticals. “Our facility is reemerging from a prior closure and has been a staple of the Decatur community since 1952. We anticipate that the new site will help create jobs, economic growth, and enhance healthcare accessibility.”

About Rising Pharmaceuticals

Rising Pharmaceuticals, a portfolio company of H.I.G. Capital, is a leading provider of generic and specialty-branded pharmaceuticals in the U.S. Rising focuses on the development, regulatory, and commercial aspects of the product life cycle while outsourcing certain manufacturing to its network of strategic CMO and CDO partners. The Company is based in New Brunswick, New Jersey, and is expanding its manufacturing footprint with a new facility in Decatur, Illinois. For more information about the Company, please visit www.risingpharma.com.

Contacts

For Media Inquiries:
Marina Wissa, (201) 961 9013
mediainquiries@risingpharma.com

Glenn Silver, (646) 871-8485
Glenn.Silver@finnpartners.com

For Customer Service Inquiries:
Jason Eisner, (201) 961 9000
customerservice@risingpharma.com

Rising Pharma Holdings Inc.


Release Versions

Contacts

For Media Inquiries:
Marina Wissa, (201) 961 9013
mediainquiries@risingpharma.com

Glenn Silver, (646) 871-8485
Glenn.Silver@finnpartners.com

For Customer Service Inquiries:
Jason Eisner, (201) 961 9000
customerservice@risingpharma.com

More News From Rising Pharma Holdings Inc.

Rising Pharmaceuticals to Support Phase 2 Clinical Trial of Chloroquine Phosphate for Prophylaxis Against COVID-19 in Healthcare Workers at Risk for COVID-19

EAST BRUNSWICK N.J.--(BUSINESS WIRE)--Rising Pharma Holdings Inc., the pharmaceutical company now operating as Rising Pharmaceuticals, today announced the support of a Phase 2 clinical trial designed to determine the clinical efficacy of chloroquine phosphate (CQ) in preventing coronavirus disease 2019 (COVID-19) in healthcare workers with moderate to high risk of exposure to SARS-CoV-2, the virus that causes COVID-19. Researchers at Columbia University are conducting this critical study to ass...

Rising Pharmaceuticals to Support Global Clinical Trial Conducted by the CROWN Collaborative (represented by Washington University School of Medicine in the US), Investigating an Innovative Approach to Protecting Essential Healthcare Workers

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Rising Pharma Holdings Inc., the pharmaceutical company operating as Rising Pharmaceuticals, today announced that it is donating chloroquine to the U.S. arm of the Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION (CROWN CORONATION) clinical trial. The CROWN CORONATION trial has been funded by the COVID-19 Therapeutics Accelerator, a partnership of philanthropic organizations and individuals, including the Bill & Melinda Gates F...

Rising Pharmaceuticals & Laurus Labs to Support a Phase 2 Randomized Clinical Trial of Hydroxychloroquine for Prophylaxis Against COVID-19 in Patients Receiving Cancer Therapy

EAST BRUNSWICK N.J.--(BUSINESS WIRE)--Rising Pharma Holdings, Inc., operating as Rising Pharmaceuticals, today announced the donation of Hydroxychloroquine tablets in support of a Phase 2 randomized clinical trial exploring hydroxychloroquine as preventive treatment for coronavirus disease 2019 (COVID-19) in patients with cancer who are receiving radiation therapy. The trial is being conducted at Memorial Sloan Kettering Cancer Center (MSK), a global leader in cancer care. The randomized, place...
Back to Newsroom